Cytochroma Announces Changes to its Board of Directors
Feb 14, 2012, 08:00 ET
MARKHAM, ON, Feb. 14, 2012 /CNW/ - Cytochroma today announced that Ms. Ela Borenstein has joined its Board of Directors and that Dr. Peter Moldt and Mr. Osamu Otani have stepped down. The number of Directors currently stands at five.
"We are delighted that Ela Borenstein has agreed to join the Cytochroma Board. She brings a wealth of experience in regulatory affairs, product development strategy and corporate governance, and will be an invaluable resource for Cytochroma," stated Dr. Alan Lewis, Chairman. "We also are grateful for the excellent service rendered by both Peter Moldt and Osamu Otani as Directors, and we wish them well."
Ms. Borenstein is Partner, Health Venture Fund at the Business Development Bank of Canada (BDC). She joined BDC in 2007 with over 20 years of management, entrepreneurial and consulting experience in the biopharmaceutical industry. Prior to joining BDC, she held the positions of Chief Operating Officer and Vice President of Clinical, Regulatory Affairs and Product Strategy for various biotech companies, as well as Senior Vice President of Scientific Affairs for Technilab Pharma. Ms. Borenstein's diversified background includes senior management responsibilities in drug and medical device development as well as key involvement in product acquisition and M&A activities. She has experience in the building of multi-disciplinary teams involved in all aspects of research and product development. Ms. Borenstein is currently serving on the boards of several portfolio companies of BDC's Health Venture Fund. Ms. Borenstein holds a B.Sc. (Honours) in Chemistry from the University of Western Ontario, a M.Sc. in Pharmacology from the University of Toronto and an MBA in Bio-Industries from Université du Québec à Montréal.
Cytochroma is a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary products to treat and prevent the clinical consequences of vitamin D insufficiency and secondary hyperparathyroidism associated with chronic kidney disease (CKD). The Company specializes in developing new therapies which are designed to safely and effectively treat patients with stage 3, 4 or 5 CKD. Cytochroma also has a portfolio CYP24 and phosphate-uptake inhibitors in early stage development.
For more information about Cytochroma, please visit www.cytochroma.com.
For further information:
Executive Director, Corporate Development
Tel: +1 (905) 479-5306 ext. 333
Robert Stanislaro (Financial Dynamics)
Tel: +1 (212) 850-5657
Share this article